Optimer Pharmaceuticals to Present at September 2009 Investor Conferences

Thursday, September 17, 2009 General News
Email Print This Page Comment
Font : A-A+

SAN DIEGO, Calif., Sept. 3 Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that the Company will present at the following investor conferences:

(Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)

Live audio webcasts of these presentations will be accessible on the Investors page of the Company's website at www.optimerpharma.com, under the investors section. Replays of these presentations will be available at the same location for 30 days following the meeting.

About Optimer Pharmaceuticals

Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative anti-infective products to treat serious infections and address unmet medical needs. Optimer has two late-stage anti-infective product candidates under development. Fidaxomicin, formerly known as OPT-80, is the only antibiotic therapy currently in Phase 3 worldwide clinical development for Clostridium difficile infection. Prulifloxacin is an antibiotic which has completed two Phase 3 clinical trials for the treatment of travelers' diarrhea, a form of infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.

-- Robert W. Baird 2009 Health Care Conference on Wednesday, September 9, 2009 at 10:30 a.m. Eastern Time at the Four Seasons Hotel in New York City. -- Thomas Weisel Partners 2009 Healthcare Conference on Thursday, September 10, 2009 at 3:50 p.m. Eastern Time at the Four Seasons Hotel in Boston. -- ThinkEquity's 6th Annual Growth Conference on Tuesday, September 15, 2009 at 10:30 a.m. Pacific Time at the St. Regis Hotel in San Francisco. -- UBS Global Life Sciences Conference 2009 on Tuesday, September 22, 2009 at 1:00 p.m. Eastern Time at the Grand Hyatt New York in New York City.

SOURCE Optimer Pharmaceuticals, Inc.


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook